Piper Sandler assumed coverage on shares of Hinge Health (NYSE:HNGE - Free Report) in a research note published on Monday, MarketBeat reports. The firm issued an overweight rating and a $41.00 price target on the stock.
A number of other research firms also recently issued reports on HNGE. Evercore ISI started coverage on Hinge Health in a research note on Monday. They set an "outperform" rating and a $50.00 price target for the company. KeyCorp started coverage on Hinge Health in a research note on Monday. They set an "overweight" rating and a $45.00 price target for the company. Canaccord Genuity Group started coverage on Hinge Health in a research note on Monday. They set a "buy" rating and a $52.00 price target for the company. Bank of America started coverage on Hinge Health in a research note on Monday. They set a "buy" rating and a $42.00 price target for the company. Finally, Needham & Company LLC began coverage on Hinge Health in a research note on Monday. They set a "buy" rating and a $47.00 price target for the company. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $46.00.
Get Our Latest Analysis on Hinge Health
Hinge Health Stock Performance
Shares of Hinge Health stock traded up $1.80 during trading hours on Monday, reaching $36.65. 802,221 shares of the stock traded hands, compared to its average volume of 817,776. Hinge Health has a one year low of $33.42 and a one year high of $43.80.
Hinge Health Company Profile
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Further Reading
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
